Approval · Notice of Compliance 27908 · 2022
NAT-ZOLMITRIPTAN: Notice of Compliance 27908
Issued April 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27908
- Date
- April 4, 2022
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update Labelling
- Canadian reference product
- ZOMIG (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-ZOLMITRIPTAN | Not yet assigned | — |
Medicinal ingredients
- ZOLMITRIPTAN 2.5 MG per TAB